Robert Yoon
YOU?
Author Swipe
View article: Inclusion of Older Adults in Early-Phase Cancer Clinical Trials: Safety, Efficacy and a Way Forward
Inclusion of Older Adults in Early-Phase Cancer Clinical Trials: Safety, Efficacy and a Way Forward Open
Early-phase clinical trials (EPCTs) are critical for evaluating the safety, tolerability, efficacy and pharmacokinetics of novel oncology therapies. However, older adults are underrepresented in all phases of oncology clinical trials, incl…
View article: Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter?
Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter? Open
Introduction Fluoropyrimidine and oxaliplatin‐based adjuvant chemotherapy delivered as 5‐fluorouracil, leucovorin and oxaliplatin (FOLFOX), or capecitabine and oxaliplatin (CAPOX) is the standard of care for resected stage III colon cancer…
View article: Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT
Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT Open
This demonstrates that a high inflammatory state represented by an NLR ≥2, both at baseline and sustained, is prognostic and predictive of response in patients receiving FLOT or CROSS. Baseline hypoalbuminaemia is predictive of poorer outc…
View article: Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers
Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers Open
Introduction: Treatment of oesophageal (OC), gastro-oesophageal junction (GOJ), and gastric cancer (GC) includes either neoadjuvant Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) for OC or GOJ or perioperative 5…